HCC patients with tumors \>5 cm in diameter, regardless of involvement in the intrahepatic and extrahepatic portal branches participated in the study. Patients were randomized allocated in liver transplantation (LT) only group and LT plus ADV-TK therapy group. All patients received orthotopic liver transplantation; in the LT plus ADV-TK group, ADV-TK therapy was delivered to patients twice.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
81
Orthotopic LT
Overall survival rate
Time frame: up to 3-year
Recurrence-free survival rate
Time frame: up to 3-year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.